FcRn-Targeted Therapies for Autoimmune Disorders | March 23-25 | Virtual Event
March 23 - 25, 2021 - KS USAdam Griffiths
info@hansonwade.com
Phone:(+1) 617 455 4188
Enhance Our Understanding of FcRn's Biology and MoA to Improve Clinical Success, Maximize its Utility and Novel Therapeutic Applications The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis, half-life extension, and recycling of human serum albumin and IgG, however in the case of more than 100+ rare and autoimmune disorders, this can not only be detrimental, but lethal to the health of the individual. Following the high profile JandJ-Momenta deal, UCB's rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx's efgartigimod awaits US filing by the end of 2020, other large players are poised to bring their candidates through the clinic in rapid succession. The digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases. The 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body. Join 100+ experts online from companies such as CSL Behring, Eli Lilly, Roche, Momenta, Alexion, Argenx and more to discuss FcRn MOA, preclinical model selection and translation, high throughput assays for ligand screening, IgG engineering, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.